Vivos (RDGL) EBIT Growth (3y) (2013 - 2025)
Vivos (RDGL) EBIT Growth (3y) (2013 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | -3.76% |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | 8.39% |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | 6.17% |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | 25.88% |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | 7.13% |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | 75.54% |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | -2.70% |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | 34.83% |
| 10 | Vivos | 27.16 Mn | 25.60 Mn | -3,105.00 | -15.80% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -15.80% |
| Sep 30, 2025 | -24.22% |
| Jun 30, 2025 | 5.02% |
| Mar 31, 2025 | -4.93% |
| Dec 31, 2024 | -44.70% |
| Sep 30, 2024 | -63.03% |
| Jun 30, 2024 | 34.44% |
| Mar 31, 2024 | -34.90% |
| Dec 31, 2023 | -47.26% |
| Sep 30, 2023 | -74.94% |
| Jun 30, 2023 | -92.37% |
| Mar 31, 2023 | -27.30% |
| Dec 31, 2022 | -29.55% |
| Sep 30, 2022 | 23.01% |
| Jun 30, 2022 | -65.73% |
| Mar 31, 2022 | -49.17% |
| Dec 31, 2021 | 49.77% |
| Sep 30, 2021 | -12.43% |
| Jun 30, 2021 | -75.68% |
| Mar 31, 2021 | 6.40% |